WO2023081434A3 - Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies - Google Patents

Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies Download PDF

Info

Publication number
WO2023081434A3
WO2023081434A3 PCT/US2022/049069 US2022049069W WO2023081434A3 WO 2023081434 A3 WO2023081434 A3 WO 2023081434A3 US 2022049069 W US2022049069 W US 2022049069W WO 2023081434 A3 WO2023081434 A3 WO 2023081434A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
methods
covid
infections
Prior art date
Application number
PCT/US2022/049069
Other languages
French (fr)
Other versions
WO2023081434A2 (en
Inventor
Ned BRAUNSTEIN
Edward Cox
Eduardo FORLEO NETO
Gary Herman
Meagan O'BRIEN
Kenneth Turner
David WEINREICH
George D. Yancopoulos
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of WO2023081434A2 publication Critical patent/WO2023081434A2/en
Publication of WO2023081434A3 publication Critical patent/WO2023081434A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods for preventing and treating SARS-CoV-2 infections, COVID-19, or symptoms thereof. The methods of the invention feature the administration of one or more antigen-binding molecules (e.g., antibodies) that bind a surface protein of SARS-CoV-2 (e.g., spike protein).
PCT/US2022/049069 2021-11-07 2022-11-06 Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies WO2023081434A2 (en)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US202163276658P 2021-11-07 2021-11-07
US63/276,658 2021-11-07
US202163278459P 2021-11-11 2021-11-11
US63/278,459 2021-11-11
US202163291226P 2021-12-17 2021-12-17
US63/291,226 2021-12-17
US202263312182P 2022-02-21 2022-02-21
US63/312,182 2022-02-21
US202263327292P 2022-04-04 2022-04-04
US63/327,292 2022-04-04
US202263416457P 2022-10-14 2022-10-14
US63/416,457 2022-10-14
US202263416879P 2022-10-17 2022-10-17
US63/416,879 2022-10-17

Publications (2)

Publication Number Publication Date
WO2023081434A2 WO2023081434A2 (en) 2023-05-11
WO2023081434A3 true WO2023081434A3 (en) 2023-06-15

Family

ID=84520011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/049069 WO2023081434A2 (en) 2021-11-07 2022-11-06 Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies

Country Status (2)

Country Link
TW (1) TW202337896A (en)
WO (1) WO2023081434A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
US7737725B1 (en) 2008-04-04 2010-06-15 Xilinx, Inc. Device control register for a processor block
PL2808393T3 (en) 2009-06-02 2018-04-30 Regeneron Pharmaceuticals, Inc. Fucosylation-deficient cells
TWI635098B (en) 2013-02-01 2018-09-11 再生元醫藥公司 Antibodies comprising chimeric constant domains
EP3277725B1 (en) 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021045836A1 (en) * 2020-04-02 2021-03-11 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
ALINA BAUM ET AL: "Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies", SCIENCE, 15 June 2020 (2020-06-15), US, pages eabd0831, XP055707765, ISSN: 0036-8075, DOI: 10.1126/science.abd0831 *
BRUEL TIMOTHÉE ET AL: "Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies", NATURE MEDICINE, NATURE PUBLISHING GROUP US, NEW YORK, vol. 28, no. 6, 23 March 2022 (2022-03-23), pages 1297 - 1302, XP037898380, ISSN: 1078-8956, [retrieved on 20220323], DOI: 10.1038/S41591-022-01792-5 *
COPIN RICHARD ET AL: "The monoclonal antibody combination REGN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies", CELL, ELSEVIER, AMSTERDAM NL, vol. 184, no. 15, 5 June 2021 (2021-06-05), pages 3949, XP086700962, ISSN: 0092-8674, [retrieved on 20210605], DOI: 10.1016/J.CELL.2021.06.002 *
DEEKS EMMA D.: "Casirivimab/Imdevimab: First Approval", DRUGS, vol. 81, no. 17, 30 October 2021 (2021-10-30), NZ, pages 2047 - 2055, XP093023731, ISSN: 0012-6667, Retrieved from the Internet <URL:https://link.springer.com/article/10.1007/s40265-021-01620-z/fulltext.html> DOI: 10.1007/s40265-021-01620-z *
EUROPEAN MEDICINES AGENCY: "Assessment report Regeneron Ireland DAC use of casirivimab and imdevimab for the treatment of COVID-19", 25 February 2021 (2021-02-25), XP055939519, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/referral/regn-cov2-antibody-combination-casirivimab/imdevimab-covid19-article-53-procedure-assessment-report_en.pdf> *
HANSEN JOHANNA ET AL: "Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail", SCIENCE, vol. 369, no. 6506, 21 August 2020 (2020-08-21), US, pages 1010 - 1014, XP055864281, ISSN: 0036-8075, Retrieved from the Internet <URL:https://www.science.org/doi/pdf/10.1126/science.abd0827?casa_token=nwcFDFSirxYAAAAA:gLprG5E4PhWD6flS0vrfFIRROvQu66E4Xx4ulVRklCrg7GxswfkjRmyrFpVLzNN3xZ6o-Sqlg2LAnQ> DOI: 10.1126/science.abd0827 *
MAZZAFERRI FULVIA ET AL: "Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron Variant of Concern", MEDRXIV, 9 May 2022 (2022-05-09), XP055935581, Retrieved from the Internet <URL:https://www.medrxiv.org/content/10.1101/2022.05.06.22274613v1> [retrieved on 20220627], DOI: 10.1101/2022.05.06.22274613 *
TATHAM LEE ET AL: "Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18-hACE2 mice", BIORXIV, 24 January 2022 (2022-01-24), XP093023740, Retrieved from the Internet <URL:https://www.biorxiv.org/content/10.1101/2022.01.23.477397v1> [retrieved on 20230214], DOI: 10.1101/2022.01.23.477397 *
URAKI RYUTA ET AL: "Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 607, no. 7917, 16 May 2022 (2022-05-16), pages 119 - 127, XP037898728, ISSN: 0028-0836, [retrieved on 20220516], DOI: 10.1038/S41586-022-04856-1 *
WEINREICH DAVID M ET AL: "REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 384, no. 3, 17 December 2020 (2020-12-17), US, pages 238 - 251, XP055848620, ISSN: 0028-4793, Retrieved from the Internet <URL:https://www.nejm.org/doi/pdf/10.1056/NEJMoa2035002?articleTools=true> DOI: 10.1056/NEJMoa2035002 *
WIEGAND TANNER ET AL: "The Rise and Fall of SARS-CoV-2 Variants and Ongoing Diversification of Omicron", VIRUSES, vol. 14, no. 9, 10 September 2022 (2022-09-10), pages 2009, XP093023663, Retrieved from the Internet <URL:https://www.mdpi.com/1999-4915/14/9/2009> DOI: 10.3390/v14092009 *

Also Published As

Publication number Publication date
WO2023081434A2 (en) 2023-05-11
TW202337896A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
WO2017156500A8 (en) TGFβ1-BINDING IMMUNOGLOBULINS AND USE THEREOF
MA40801A1 (en) Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123
WO2016207304A3 (en) Monoclonal anti-il-1racp antibodies
MX2022014852A (en) METHODS FOR TREATING OR PREVENTING SARS-CoV-2 INFECTIONS AND COVID-19 WITH ANTI-SARS-CoV-2 SPIKE GLYCOPROTEIN ANTIBODIES.
WO2020169755A3 (en) Antibodies
WO2020146902A3 (en) Anti-variable muc1* antibodies and uses thereof
CA3179819A1 (en) Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2022204316A3 (en) Variant nucleic acid libraries for cd3
PE20230381A1 (en) RGMA BINDING PROTEIN
EA201792329A1 (en) METHOD OF MONOMERIZATION OF RECOMBINANT ANTIBODY MOLECULES
WO2022167816A3 (en) Antibodies
WO2019066435A3 (en) Anti-bcma antibody having high affinity for bcma and pharmaceutical composition for treatment of cancer, comprising same
WO2021231800A3 (en) Anti-hemojuvelin (hjv) antibodies for treating anemia of chronic disease
WO2021212021A3 (en) Coronavirus antibodies and methods of use thereof
WO2021259927A3 (en) Anti-cd2 antibodies
WO2022023566A3 (en) Cd-3 antibodies for the treatment of coronavirus
WO2023081434A3 (en) Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies
WO2022011110A3 (en) Compositions and methods for the diagnosis and treatment of sars-cov-2 virus infection
ATE543906T1 (en) ANTIGEN OF STREPTOCOCCUS FROM GROUP B
WO2022026592A3 (en) Antibody molecules to coronavirus and uses thereof
WO2022058618A3 (en) Sars-cov2 antibodies
UA91683C2 (en) Antibodies directed against amyloid-beta peptide and methods using same
AR107012A1 (en) ANTIBODY THAT JOINS SPECIFICALLY TO ErbB3 AND THE USE OF IT
WO2021032860A3 (en) Anti-c7 antibody or antibody fragment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22823200

Country of ref document: EP

Kind code of ref document: A2